innovative methods of application of stem cells in medicine
DESCRIPTION
POLISH PROJECT ON VERY SMALL EMBRYONIC-LIKE STEM CELLS (VSELs) IN CARDIOLOGY. INNOVATIVE METHODS OF APPLICATION OF STEM CELLS IN MEDICINE. Michał Tendera MD Wojciech Wojakowski MD THIRD DIVISION OF CARDIOLOGY MEDICAL UNIVERSITY OF SILESIA, KATOWICE, POLAND. VSELs. - PowerPoint PPT PresentationTRANSCRIPT
INNOVATIVE METHODS OF APPLICATION OF STEM CELLS IN MEDICINE
Michał Tendera MDWojciech Wojakowski MD
THIRD DIVISION OF CARDIOLOGYMEDICAL UNIVERSITY OF SILESIA, KATOWICE, POLAND
POLISH PROJECT ON VERY SMALL EMBRYONIC-LIKE STEM CELLS(VSELs) IN CARDIOLOGY
VSELs
Cytometry A. 2009 January; 75(1): 4–13.
IMAGE STREAM
Cytometry A. 2009 January; 75(1): 4–13.
Sca-1+lin-CD45+
Sca-1+lin-CD45-
2 m 2 m 2.5 m
1 m 2 m
4 m
A
B
1 m 1 m
Kucia et al. Leukemia 2006,20:857-869
TEM of murine Sca-1+lin- CD45- (VSEL) and Sca-1+lin- CD45+ (HSC) cells
VSELs ARE PROGENY OF EPIBLAST-DERIVED CELLS
Shin et al. Leukemia, 2009: 23(11): 2042
REGULATION OF QUIESCENCE AND PLURIPOTNCY
RECOVERY OF GENOMIC IMPRINTING DURING FORATION OF VSEL-DS
Shin et al. Leukemia, 2009: 23(11): 2042
REGULATION OF QUIESCENCE AND PLURIPOTNCY
MURINE VSEL-DERIVED CM
C2C12 myoblasts7 days
Re-sorting
GFP+ VSEL
Tripsinization
GFP+ VSEL
C2C12
C2C12
DMEM + 2% FBS37oC, 5% CO2.
Wojakowski et al. Int J Onc, 2010, in press
VSEL-DERIVED CM
5x104 CELLS
CA
RD
IAC
DIF
FE
RE
NT
IAT
ION
0
20
40
60
80
100
120
Nkx 2.5/Csx GATA-4 Troponin I Mybpc3 actinin 2 actinin 3
MNC
VSEL
DAY 4
DAY 6
DAY 9
DAY 12
DAY 16
m
RN
A(f
old-
diff
eren
ce)
Wojakowski et al. Int J Onc, 2010, in press
VSEL-DERIVED CM
SORT II
Cardiac pre-differen.
VSEL Expansion culture
C2C12 feeder layer 9 days
EGFP transgenic mice [C57BL/6]
BM isolation SORT I
VSELs
HCSs
WT mice [C57BL/6]
afterinfarction
Injection 5 days6 monthsof follow-up
Injection
MURINE MODEL OF ACUTE MI
0
10
20
30
40
50
60
70
80
0.0
0.2
0.4
0.6
0.8
1.0
1.2
0
1
2
3
4
5
6
7
* † * † * †
%
BSL 48 h 1 mo 3 mo 6 mo
LV Ejection Fraction
mm
† * †
BSL 48 h 1 mo 3 mo 6 mo
LV End-systolic Diameter
Infarct Wall Thickness(Diastole)
* †
BSL 48 h 1 mo 3 mo 6 mo
mm
* P < 0.05 vs. Vehicle-treated † P < 0.05 vs. HSCs
Gr I (Vehicle)
Gr II (HSCs)
Gr III (VSELs expanded and pre-differentiated)
IMPROVEMENT OF LV FUNCTION
Zuba-Surma EK et al. Circulation (AHA 2008)
Zuba-Surma EK et al. Circulation (AHA 2008)
EGFP+ MYOCYTES AFTER 6 MONTHS
VSEL-DERIVED CM
STUDY LIMITATIONS
limited gene-array and no proteomic data no EP data
murine transplantation model
RESEARCH PLAN
comparision with ESC-derived CM throughout differentiation electrophysiology study differentiation of human BM-VSELs implantation of EGFP+ VSELs in murine model of reperfused MI
HUMAN VSELS
Cytometry A. 2009 January; 75(1): 4–13.
CIRCULATION OF VSELs
MOBILIZATION OF VSELS
Wojakowski, W. et al. J Am Coll Cardiol 2009;53:1-9
Peripheral BloodBone MarrowSkeletal MuscleOther Tissues
MYOCARDIAL INFARCTION
MOBILIZATION OF CXCR4+ CELLSIncreased Expression ofCardiac/Endothelial Markers
Mobilization Homing/Engraftment
Kucia et al.. Circulation Res. 2004, 95:1191-9Ratajczak et al.. Biol. Cell 2005, 97:113-146. Wojakowski et al. Heart 2008 94(1):27-33
HUMAN VSELs
Wojakowski, W. et al. J Am Coll Cardiol 2009;53:1-9
13.5µm
12.4µm
Monocytes
Granulocytes
Lymphocytes
8.4µm
Erythrocytes
7.5µm
VSEL
7.04 µm
MOBILIZATION OF VSELs
MOBILIZATION OF VSELs INDUCED BY ISCHEMIC STROKE
Paczkowska, E. et al. Stroke 2009;40:1237-1244
MOBILIZATION BY PHYSICAL EXERCISE
HEALTHY SUBJECTS AND PATIENTS WITH FIRST ACUTE MI <45y
VSEL analysis
VSEL 0h (p
rzed
wys
iłkie
m)
VSEL 2h p
o wys
iłku
VSEL 6h p
o wys
iłku
-0.05
0.00
0.05
0.10
0.15
0.20
0.25
p=0,0344
% o
f ev
ents
in V
SE
L g
ate
HYPOTHESIS : MOBILIZATION OF VSELs AND THEIR FUNCTION IS REDUCED IN PATIENTS WITH HEART FAILURE
MOBILIZATION
MOBILIZATION OF VSELS DURING HEART SURGERY
Mieno, S. et al. Circulation 2006;114:186-192
SDF-1
MOBILIZATION OF VSELs DURING CARDIAC SURGERY
CHILDREN VS. ADULTS
GENE EXPRESSION PROFILE
ON-PUMP VS. OFF-PUMP
PRESENCE OF VSELs IN HUMAN HEART
AIMS
Bone marrow
Thymus10m
Spleen
Brain
Heart
Pancreas
Kidneys
Liver Skeletal muscles
Testes
Lungs
Oct-4 and 7-AAD
Oct-4 and 7-AAD
Images of Oct-4+ VSELs from organs – by ImageStream system
CLINICAL APPLICATION
REGENT
LABELLING
ANTI-CD34
II STEP
LABELLINGANTI-CXCR4
I STEP
CD34+CXCR4+
PT SELECTION
RANDOMIZATION
UNSELECTED SELECTED CONTROL
CELL INFUSION
MRI + VENTRICULO + CLINICAL F-U
CELL INFUSION
MRI + CLIN F-U
MRI
VENTRICULO VENTRICULO
6 MONTHS
Tendera et al..Eur Heart J. 2009 Jun;30(11):1313-21.
CLINICAL APPLICATION
REGENT
Tendera et al..Eur Heart J. 2009 Jun;30(11):1313-21.
LVEF (M RI)
Med ian 25%-75% MIn .-Max.
C ontrols U nselected Selected
-20
-10
0
10
20
30
40
50
LV
EF
[%]
p=0.17 p=0.75
p=0.19
-4 3 5
Wilcoxon test
Changes of LVEF for patients w ith in itia l LVEF <m edian (37% )
G roup 'selected'
0 6 months10
20
30
40
50
60
G roup 'unselected'
0 6 months10
20
30
40
50
60
p=0.01 p=0.00736
3129.5
34.5
INTRACORONARY RADIOLABELLED SELECTED 34+ CELLS
Musiałek et al., TCT 200999mTc-extametazime-labeled
CLINICAL APPLICATION
REGENT-VSELs
„Randomized, prospective, double-blinded, placebo controlled trial to assess the effects of BM-derived immunoselected CD133+ cells on LV perfusion and function in patients with inducible ischemia and refractory angina”
1. Efficiency of intracoronary infusion of BM-derived CD133+ cells after succesful recanalization of the CTO of the artery in patients with reractory angina and incucible ischemia.
2. Efficiency of NOGA-guided direct intramyocardial injection of BM-derived CD133+ cells in patients with reractory angina and incucible ischemia ineligible for recanalization of CTO.
AIMS
PODZADANIE 7.5
INCLUSION CRITERIA
60 patients with CTO in qualifying angiogram scheduled for PCI
Inclusion criteria: angina CCS class ≥2, symptoms despite optimal medical therapy, chronic total occlusion of the artery supplying viable myocardium, LVEF ≤ 50%, ineligible for surgical revascularization
Exclusion criteria: acute coronary syndrome, myocardial infarction < 3 months, LVEF <30%, renal failure (GFR <30 mL/min/1.73m2), malignancy, bleeding diathesis
PROTOCOL
CELLS ISOLATION (CliniMACS)
RANDOMIZATION
CTO PCI
SCREENING
INFORMED CONSENT
SUCCESSFUL
1. Clinical evaluation: CCS, NYHA, quality of life2. Exercise test3. SPECT imaging4. MRI
UNSUCCESSFUL
INTRACORONARY CD133+ CELLS
INTRAMYOCARDIAL CD133+ CELLS
PLACEBOPLACEBO
1. Clinical evaluation: CCS, NYHA, quality of life2. Exercise test3. SPECT imaging4. MRI
BASE
LIN
E3
MO
NTH
S
Warszawa, 09.01.2010Innowacyjne metody wykorzystania komórek macierzystych w medycynie30
PODZADANIE 7.5
PROGRESSION OF ATHEROSCLEROSIS
1. INRAVASCULAR ULTRASOUND WITH VH2. OPTICAL COHERENCE TOMPGRAPHY3. MICROCIRCULATORY FUNCTION4. ENDOTHELIAL REACTIVITY
1. CARDIAC DIFFERENTIATION OF BM-DERIVED VSELS
2. MOBILIZATION AND FUNCTION OF CIRCULATING VSELS IN PATIENTS WITH HF, MI <45y AND UNDERGOING CARDIAC SURGERY
3. PHYSICAL EXERCISE AND MOBILIZATION
4. PRESENCE OF VSELs IN HUMAN HEARTS AND ARTERIES
5. CLINICAL TRIAL
SUMMARY
TEAM
III DIVISION OF CARDIOLOGY MEDICAL UNIVERSITY OF SILESIA
BONE MARROW TRANSPLANT UNITDEPARTMENT OF HEMATOLOGY
MEDICAL UNIVERSITY OF SILESIA
STEM CELL INSTITUTEUNIVERSITY OF LOUISVILLE
DEPARTMENT OF CHILDREN CARDIAC SURGERY
JAGIELLONIAN UNIVERSITY
DEPARTMENT OF CARDIAC SURGERYMEDICAL UNIVERSITY OF SILESIA
DEPARTMENT OF BIOTECHNIOLOGY
JAGIELLONIAN UNIVERSITY